Xilio Therapeutics (NASDAQ:XLO) Announces Quarterly Earnings Results

Xilio Therapeutics (NASDAQ:XLO) announced its quarterly earnings results on Thursday. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.26, FiscalAI reports. The business had revenue of $18.69 million during the quarter, compared to analysts’ expectations of $12.72 million. Xilio Therapeutics had a negative return on equity of 71.99% and a negative net margin of 34.06%.

Xilio Therapeutics Stock Up 1.8%

XLO traded up $0.16 during trading on Friday, hitting $9.17. The company’s stock had a trading volume of 8,113 shares, compared to its average volume of 21,629. The firm’s 50 day moving average price is $8.90 and its two-hundred day moving average price is $8.37. Xilio Therapeutics has a 12 month low of $6.47 and a 12 month high of $12.74. The stock has a market capitalization of $60.34 million, a price-to-earnings ratio of -5.59 and a beta of -0.14.

Wall Street Analysts Forecast Growth

XLO has been the topic of several research analyst reports. Wall Street Zen downgraded Xilio Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings cut Xilio Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 6th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Xilio Therapeutics currently has an average rating of “Sell”.

Hedge Funds Weigh In On Xilio Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC acquired a new stake in shares of Xilio Therapeutics during the fourth quarter worth $27,000. Velan Capital Investment Management LP bought a new position in Xilio Therapeutics during the fourth quarter worth about $109,000. State Street Corp grew its position in shares of Xilio Therapeutics by 13.7% in the 4th quarter. State Street Corp now owns 186,390 shares of the company’s stock valued at $119,000 after purchasing an additional 22,500 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Xilio Therapeutics by 68.3% during the fourth quarter. Renaissance Technologies LLC now owns 344,416 shares of the company’s stock worth $220,000 after acquiring an additional 139,716 shares during the period. Finally, Squarepoint Ops LLC increased its holdings in Xilio Therapeutics by 39.6% during the 3rd quarter. Squarepoint Ops LLC now owns 328,794 shares of the company’s stock worth $277,000 after purchasing an additional 93,338 shares in the last quarter. Institutional investors own 54.29% of the company’s stock.

Xilio Therapeutics Company Profile

Xilio Therapeutics is a clinical?stage biotechnology company focused on the discovery and development of tumor?targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro?drug versions of potent immune?modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin?12 (IL?12) and interleukin?2 (IL?2) molecules fused to tumor?binding antibodies or peptide ligands.